ARTIVA BIOTHERAP.DL-,0001 Aktie

Artiva Biotherapeutics presented its allogeneic NK-cell therapy AlloNK and reported an ACR50 response rate of 71% in 21 therapy-refractory rheumatoid arthritis patients. The company reports no CRS and no ICANS in the safety database and considers the profile suitable for office-based practices. The FDA agreed to a Phase III design with about 150 patients (2:1 randomization, primary endpoint ACR50 at six months); Artiva expects study readout in 2028 and financial runway through 2029. A parallel basket study is underway in Sjögren’s, sclerosis and myositis; projected manufacturing costs are about $8,000 per treatment. » More on de.investing.com

Artiva Biotherapeutics reports that 71% of treatment‑resistant rheumatoid arthritis patients in a Phase‑2a study achieved an ACR50 response after at least six months, with no relapses or need for new immunomodulatory therapies. The AlloNK therapy showed a tolerable safety profile and prompted a premarket share rise of about 6%. Artiva agreed with the FDA on a single pivotal randomized Phase‑3 study (AlloNK plus Rituximab vs. Rituximab) with roughly 150 patients, planning to start in H2 2026. The company plans a capital raise of about $300m (23,871,526 shares at $11.52 plus warrants); Q1 loss was $23.5m and cash on hand was $86.8m as of 31 March 2026. » More on de.investing.com

Artiva Biotherapeutics named Thad Huston chief financial officer effective Feb. 18. Huston brings more than 30 years of experience in pharma and medical devices; his annual salary is $540,000 plus a variable cash bonus of up to 40%. He will receive 220,000 RSUs that vest over four years and contractually agreed severance payments on termination or change of control. Additionally, Elaine Sorg was appointed to the board, and Artiva announced presentations of data on its AlloNK therapy AB-101 that suggest higher cost-efficiency versus CAR-T. » More on de.investing.com